olmesartan

Patients were randomized to one of 12 treatments involving amlodipine, olmesartan, or placebo, in combination therapy or mono therapy.

The higher rate of fatal cardiovascular events with olmesartan among patients with preexisting coronary heart disease is of concern.

The combination of olmesartan with a diuretic has a stronger effect on BP lowering compared to olmesartan or diuretic alone.

And what are the special benefits of olmesartan-based combination compared with other ARBs-based combinations?

Overall, treatment-related adverse events were not significantly increased in patients receiving olmesartan-based therapy.

What are the determinants making olmesartan the strongest anti-hypertensive ARB?

A pos-hoc analysis of ROADMAP demonstrated a "substantial BP-independent effect" of olmesartan in preventing microalbuminuria.

abstract: Objective: To evaluate the efficacy and safety of olmesartan medoxomil on hypertension in elderly patients.

According to these findings, can we conclude that treatment with olmesartan will bring more promising benefits in reducing CVD risk?

So what's the difference between olmesartan-based combination therapy and other ARBs-based combination therapy?

According to these findings can we conclude that treatment with olmesartan will bring us more promising benefits in reducing CVD risk?

Conclusion: Olmesartan medoxomil is effective and safe in the treatment of hypertension in elderly patients.

Prof. Zou Yun Zeng: I think I can explain the effects of olmesartan from three aspects.

AIM: To investigate the protective effect of olmesartan medoxomil on renal injury in mice with chronic heart failure (CHF).

Other lecturers spoke this evening about ARBs and in particular olmesartan.

Are there any particular factors that make olmesartan a stronger ARB?

Prof. Zhu : Compared to other ARBs, olmesartan has the strongest effects of BP lowering.

It is clear that olmesartan has a very good position in the armamentarium to control blood pressure.

In addition, data from the ROADMAP study proved that olmesartan can reduce risk of MAU in T2DM patients.

I think this is the effect of olmesartan complete reverse agonism and also underlying mechanism of olmesartan makes it the strongest ARB.

Antihypertensive efficacy and safety of domestic olmesartan monotherapy in mild or moderate essential hypertension

Determination of the Dissolutions of Two Components in Compound Olmesartan Medoxomil Tablets by New Vierordt Method

No Synergistic Effect of Combined Olmesartan and Temocapril on Reversal of Left Ventricular Hypertrophy

A novel synthesis of olmesartan medoxomil and examination of its related impurities

Quantitative Analysis of Olmesartan in Human Plasma by HPLC-MS With Solid-Phase Extraction

Effects and safety of mild and moderate primary hypertension treated with olmesartan medoxomil tablet

Clinical Efficacy and Safety of Olmesartan Medoxomil in Patients with Mild to Moderate Hypertension

Research Progress in Synthesis of Olmesartan Medoxomil